FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,657 | -100.0% | 164,235 | +7.3% | 0.02% | -56.1% |
| Q3 2022 | $3,429,000 | -7.7% | 153,051 | +2.0% | 0.04% | -2.4% |
| Q2 2022 | $3,716,000 | -9.1% | 150,013 | +42.2% | 0.04% | +7.7% |
| Q1 2022 | $4,090,000 | -33.6% | 105,500 | +0.2% | 0.04% | -31.6% |
| Q4 2021 | $6,159,000 | -48.2% | 105,254 | -47.5% | 0.06% | 0.0% |
| Q3 2021 | $11,890,000 | +120.2% | 200,608 | +222.5% | 0.06% | +9.6% |
| Q2 2021 | $5,400,000 | +11.2% | 62,213 | +5.6% | 0.05% | +8.3% |
| Q1 2021 | $4,854,000 | -23.8% | 58,888 | -15.9% | 0.05% | -32.4% |
| Q4 2020 | $6,369,000 | +123.4% | 70,039 | -1.8% | 0.07% | +82.1% |
| Q3 2020 | $2,851,000 | +324.3% | 71,338 | +264.0% | 0.04% | +254.5% |
| Q2 2020 | $672,000 | – | 19,597 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |